You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Engineered Cyclodextrins to Address 7-ketocholesterol-Associated Diseases ofAging

    SBC: UNDERDOG PHARMACEUTICALS, INC.            Topic: NIA

    Project Summary/Abstract Underdog Pharmaceuticals, Inc. (UDP), in collaboration with the SENS Research Foundation (SRF), aims to demonstrate that 7-ketocholesterol (7KC) is elevated in red blood cells (RBCs) in Atherosclerosis and Alzheimer’s disease. 7KC is primarily created by non-enzymatic oxidation of cholesterol. With only a few exceptions, human tissues lack the ability to metabolize or ex ...

    STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
  2. Eliminating Acne Through Photo-Inactivation Catalase

    SBC: PULSETHERA CORP            Topic: NIAMS

    PROJECT SUMMARYAcne vulgaris is a skin inflammatory condition affecting 80% of young adults and can frequently induce permanent disfigurement even with appropriate treatment. Acne is caused by C. acnes in the setting of hormonal changes and sebum induction that accompany adolescence. The mainstay of therapeutics consist of eradicating C. acnes and reducing inflammation. However, treatment is prolo ...

    STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
  3. Development of Safe in Utero Gene Editing Technology in Mice

    SBC: Acrigen Biosciences, Inc.            Topic: 100

    Abstract In the nearly 20 years since the groundbreaking sequencing of the human genome, the potential for precision genetic medicine has still not been realized. Advances in sequencing have vastly increased our ability to screen patients (including parents and fetuses) for genetic abnormalities, dramatically expanding identification of hereditary diseases in the prenatal period. This opens the do ...

    STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
  4. A therapeutic for Lyme disease based on Peptidoglycan Recognition Protein 1

    SBC: L2 DIAGNOSTICS LLC            Topic: NIAID

    ABSTRACTLyme disease, the most common vector-borne illness in North America, is caused by the spirochete B. burgdorferi. Infection begins in the skin following an infected tick-bite and acute illness is characterized by headache, fever and myalgia. Currently, there is no human vaccine against Lyme disease and therapeutic administration of antibiotics remains the recommended treatment option. In th ...

    STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
  5. CCR4-IL2 Bispecific Immunotoxin for Targeted Therapy of Cutaneous T-Cell Lymphoma

    SBC: ROCK IMMUNE LLC            Topic: 102

    Abstract Cutaneous T-cell lymphoma (CTCL) is a type of extra-nodal non-Hodgkin’s lymphoma characterized by skin lesions resulting from infiltration of malignant T lymphocytes. Mycosis fungoides and Sezary syndrome are the two most common types of CTCL. Although treatments exist, they are mainly palliative with low response and durability of response without any cure. The objective response rate ...

    STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
  6. Targeting Covid-19 with a Therapeutic Interfering Particle

    SBC: ALEPH THERAPEUTICS INC            Topic: NIAID

    SUMMARYThe Covid-19 pandemic caused by Severe Acute Respiratory Coronavirus 2 (SARS-CoV-2) is currently the most important public health crisis in the world. Given the unprecedented scope of this disease, it is critical to explore novel strategies to mitigate this crisis. Aleph Therapeutics and UCSF have jointly developed eTIP1, a Therapeutic Interfering Particle. eTIP1 was developed under a DARPA ...

    STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
  7. Using Rendever to improve the quality of life of older adults with cognitive impairments in senior living communities and their family members who live at a distance.

    SBC: RENDEVER, INC.            Topic: NIA

    ABSTRACTThe United States is experiencing a public health crisis on a massive scale due to the number of people with dementia, lack of cures, and challenges associated with caregiving for this population.1,2 until cures for the dementias are discovered, new technologies and interventions are imperative that can reduce the stress and emotional burden of Alzheimer’s disease (AD) and Alzheimer’s ...

    STTR Phase II 2021 Department of Health and Human ServicesNational Institutes of Health
  8. Development of Melanocortin-3 Receptor Peptide Agonists for the Treatment of Anorexia Nervosa

    SBC: COURAGE THERAPEUTICS INC            Topic: 101

    Anorexia nervosa (AN) is a devastating neuropsychiatric disease with a high prevalence (up to 2.2% of women) and significant morbidity and mortality. There are currently no effective therapeutic agents for the disorder. The goal of Courage Therapeutics is the development of melanocortin-3 receptor (MC3R) -specific agonist peptides for the treatment of anorexia nervosa. The product of this Phase I ...

    STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
  9. Rapid point-of-care detection of Chlamydia trachomatis in urine

    SBC: ELECTRONUCLEICS INC            Topic: NIAID

    Project Summary The goal of this project is to demonstrate feasibility of a system for the point-of-care (POC) detection of Chlamydia trachomatis (CT) in human urine samples that integrates a patented detector of pathogens based on identification of species-specific, nucleic acid (NA) sequences. The detector relies on a novel electromechanical signal transduction mechanism that enables the low-cos ...

    STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
  10. Development of a protein palmitoylation assay to monitor treatment of CLN1 Batten Disease

    SBC: Circumvent Pharmaceuticals            Topic: NICHD

    SummaryIn the Specific Aims outlined by the following proposal for an NIH SBIR Phase 1 project, we will use a multi-faceted approach to identify key substrates for targeted assay development to monitor therapy in for CLN1 Batten Disease (CLN1). CLN1 is an ultra-rare neurodegenerative disease that affects children with autosomal recessive mutations in the gene for palmitoyl-protein thioesterase 1 ( ...

    STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government